Idronoxil data provides hope to treat secondary brain cancer
Filed with ASX · · 4 pages · English
Earlier from Noxopharm
- NOX66 confirmed Non-Toxic. Trial Cleared for Full Enrolment
- St Vincents Cancer Study to Commence-NOX66 and Radiotherapy
- NOX makes strategic commitment to treatment of rare cancers
- Market Guidance for Next Six Months
- NOX Files Patent Application on Smart Idronoxil
Later from Noxopharm
- Noxopharm provides update on NOX66 Clinical Trial Program
- Suspension from Official Quotation
- Noxopharm raises $5.5 million to advance clinical program
- Reinstatement to Official Quotation
- Important Brain Cancer Findings for NOX66 Program
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm